Fatty Amides Group
These substances were identified for action under the Chemicals Management Plan (CMP). This screening assessment focuses on 3 of 12 substances referred to collectively as the Fatty Amides Group.
Information sheet
| Substance group | CAS RN | Common name | DSL name | Public comments on the draft screening assessment | Final screening assessment | Conclusion on section 64 criteria | Follow-up activities |
|---|---|---|---|---|---|---|---|
| Fatty Amides Group | 112-84-5 | Erucamide | 13-Docosenamide, (Z)- | HTML | HTML | Does not meet | None planned at this time |
| 301-02-0 | Oleamide | 9-Octadecenamide, (Z)- | |||||
| 68784-17-8Footnote a | IODA reaction products with TEPA | Isooctadecanoic acid, reaction products with tetraethylenepentamine | |||||
|
|||||||
| Date | Activity |
|---|---|
| April 27, 2019 | Publication of the final screening assessment. The related notice was published in the Canada Gazette, Part I: Vol. 153, No. 17 |
| February 24, 2018 | Publication and start of 60-day public comment period on the draft screening assessment. The related notice was published in the Canada Gazette, Part I: Vol. 152, No. 8. |
Background
Nine other substances were identified as being part of the Fatty Amides Group at the outset of the third phase of the CMP. Five of these substances (CAS RNs 68478-81-9, 71820-35-4, CDSL 11053-1, CDSL 11555-8 and CDSL 11557-1) were subsequently determined to be of low concern to both human health and the environment, through other approaches. Conclusions for these 5 substances are provided in the Screening Assessment for the Rapid Screening of Substances with Limited General Population Exposure. The remaining 4 other substances in this group (CAS RNs 120-40-1, 142-78-9, 68153-35-5 and 68603-42-9) were placed into other substance groups, to which they are more appropriately suited based on scientific considerations. Conclusions for 3 substances (CAS RNs 120-40-1, 142-78-9 and 68603-42-9) will be provided in the upcoming Alkanolamines and Fatty Alkanolamides Group assessment, while the proposed conclusion for 1 substance (CAS RN 68153-35-5) will be provided in a future screening assessment.
Page details
- Date modified: